For Hepatocellular Carcinoma, Second-Line Ramucirumab Not Better than Placebo

Share this content:
Second-line treatment with ramucirumab did not significantly improve survival over placebo in advanced hepatocellular carcinoma.
Second-line treatment with ramucirumab did not significantly improve survival over placebo in advanced hepatocellular carcinoma.

Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma, a new study published online ahead of print in the journal The Lancet Oncology has shown.

For the international, placebo-controlled, double-blind, phase III REACH trial, researchers enrolled 565 patients with advanced hepatocellular carcinoma who were refractory or not amenable to locoregional therapy and had previously received sorafenib.

Patients were randomly assigned 1:1 to receive ramucirumab 8 mg/kg IV or placebo every 2 weeks plus best supportive care until disease progression, unacceptable toxicity, or death.

RELATED: Nivolumab Shows Promising Efficacy, Safety in Advanced Hepatocellular Carcinoma

Results showed that median overall survival in the ramucirumab group was 9.2 months (95% CI: 8.0, 10.6) compared with 7.6 months (95% CI: 6.0, 9.3) in the placebo group (HR = 0.87; 95% CI: 0.72, 1.05; P=0.14), indicating there was no significant difference in overall survival between the two groups.

In regard to safety, 12% of patients in the ramucirumab group experienced grade 3 or higher hypertension compared with 4% in the placebo group.

Reference

  1. Zhu AZ, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015. [Epub ahead of print]. doi: 10.1016/S1470-2045(15)00050-9.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs